New Drugs Approved in 2020

Summary: This study aims to estimate the number of eligible cancer patients for newly approved drug-indication pairs and project the potential spending and use in the US. The findings suggest that if all eligible patients use the 2018 FDA-approved oncology drugs, there would be a $39.5 billion increase in cancer drug spending, while using the drugs in fewer than 20% of eligible patients is consistent with industry forecasts for drug spending.